NCT00826111View on ClinicalTrials.gov

The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia

PHASE4CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

July 31, 2011

Conditions
DepressionAnxietyInsomnia
Interventions
DRUG

Eszopiclone

Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.

DRUG

Placebo

Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.

Trial Locations (1)

02135

Steward St. Elizabeth's Medical Center of Boston, Inc., Boston

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Steward St. Elizabeth's Medical Center of Boston, Inc.

OTHER

NCT00826111 - The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia | Biotech Hunter | Biotech Hunter